Traynor Capital Management Inc. Grows Stock Position in Intuitive Surgical, Inc. $ISRG

Traynor Capital Management Inc. raised its stake in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 15.8% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 63,880 shares of the medical equipment provider’s stock after acquiring an additional 8,730 shares during the quarter. Intuitive Surgical makes up approximately 1.6% of Traynor Capital Management Inc.’s investment portfolio, making the stock its 11th largest position. Traynor Capital Management Inc.’s holdings in Intuitive Surgical were worth $28,569,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also made changes to their positions in the business. Tobam grew its stake in Intuitive Surgical by 666.7% in the 2nd quarter. Tobam now owns 46 shares of the medical equipment provider’s stock valued at $25,000 after acquiring an additional 40 shares during the period. Kilter Group LLC purchased a new position in Intuitive Surgical during the second quarter valued at $27,000. Princeton Global Asset Management LLC purchased a new stake in shares of Intuitive Surgical during the second quarter worth about $30,000. Riggs Asset Managment Co. Inc. raised its position in shares of Intuitive Surgical by 84.2% during the 2nd quarter. Riggs Asset Managment Co. Inc. now owns 70 shares of the medical equipment provider’s stock worth $38,000 after purchasing an additional 32 shares during the last quarter. Finally, First Command Advisory Services Inc. lifted its stake in Intuitive Surgical by 3,750.0% in the 2nd quarter. First Command Advisory Services Inc. now owns 77 shares of the medical equipment provider’s stock valued at $42,000 after buying an additional 75 shares in the last quarter. 83.64% of the stock is currently owned by hedge funds and other institutional investors.

Key Headlines Impacting Intuitive Surgical

Here are the key news stories impacting Intuitive Surgical this week:

• Positive Sentiment: FDA clears the da Vinci 5 system for select advanced cardiac procedures, widening the platform’s addressable market in minimally invasive heart surgery and supporting long‑term procedure growth. Read More.
• Positive Sentiment: TD Cowen initiated coverage with a “strong‑buy” rating, adding fresh analyst endorsement that can attract demand from institutional and retail buyers. Read More.
• Positive Sentiment: Barclays reaffirmed a buy stance on ISRG, maintaining additional sell‑side support. Read More.
• Positive Sentiment: HSBC published a bullish forecast calling for strong price appreciation, another vote of confidence from major bank research. Read More.
• Positive Sentiment: Polen Capital highlighted ISRG as a core holding in a growth strategy, indicating continued conviction from active growth managers. Read More.
• Neutral Sentiment: Coverage piece asks whether it’s time to reassess ISRG after recent share‑price weakness — useful for investors considering valuation or momentum shifts but not a direct catalyst. Read More.
• Negative Sentiment: Significant insider selling: Director Gary S. Guthart reported large sales (24,500 shares and an additional 2,800‑share sale across filings), substantially reducing his holdings — a short‑term headwind and common trigger for profit‑taking. Read More.
• Negative Sentiment: EVP Myriam Curet disclosed a smaller sale (230 shares). While modest, the sale adds to the day’s insider activity that may amplify negative sentiment. Read More.

Intuitive Surgical Trading Down 0.6%

Shares of ISRG opened at $522.04 on Thursday. The firm has a market cap of $187.14 billion, a P/E ratio of 66.16, a price-to-earnings-growth ratio of 4.27 and a beta of 1.67. The company’s 50-day moving average price is $560.68 and its 200 day moving average price is $511.75. Intuitive Surgical, Inc. has a 12-month low of $425.00 and a 12-month high of $609.08.

Intuitive Surgical (NASDAQ:ISRG) last released its quarterly earnings results on Thursday, January 22nd. The medical equipment provider reported $2.53 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.27 by $0.26. Intuitive Surgical had a net margin of 28.38% and a return on equity of 15.06%. The business had revenue of $2.87 billion for the quarter, compared to the consensus estimate of $2.72 billion. During the same period in the previous year, the firm earned $2.21 EPS. The business’s revenue was up 18.8% on a year-over-year basis. Equities research analysts forecast that Intuitive Surgical, Inc. will post 6.43 earnings per share for the current year.

Insider Activity at Intuitive Surgical

In related news, VP Fredrik Widman sold 2,067 shares of the company’s stock in a transaction that occurred on Wednesday, November 5th. The shares were sold at an average price of $550.00, for a total transaction of $1,136,850.00. Following the sale, the vice president directly owned 473 shares of the company’s stock, valued at $260,150. This represents a 81.38% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Mark Brosius sold 4,500 shares of the firm’s stock in a transaction that occurred on Friday, December 12th. The shares were sold at an average price of $547.36, for a total transaction of $2,463,120.00. Following the completion of the transaction, the senior vice president directly owned 907 shares of the company’s stock, valued at $496,455.52. This represents a 83.23% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 75,557 shares of company stock worth $42,000,903 over the last ninety days. Company insiders own 0.70% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have recently weighed in on ISRG shares. Weiss Ratings restated a “hold (c+)” rating on shares of Intuitive Surgical in a research report on Monday, December 29th. Raymond James Financial raised their target price on shares of Intuitive Surgical from $603.00 to $615.00 and gave the stock an “outperform” rating in a research note on Friday, January 23rd. BTIG Research reiterated a “buy” rating and set a $616.00 price objective on shares of Intuitive Surgical in a research report on Friday, January 23rd. TD Cowen raised Intuitive Surgical to a “strong-buy” rating in a research note on Tuesday. Finally, The Goldman Sachs Group reiterated a “buy” rating and set a $714.00 price target on shares of Intuitive Surgical in a report on Friday, January 9th. Two research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, eight have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $620.41.

Intuitive Surgical Company Profile

Intuitive Surgical, founded in 1995 and headquartered in Sunnyvale, California, is a medical technology company focused on the design, manufacture and service of robotic-assisted surgical systems. The company is best known for its da Vinci surgical systems, which enable minimally invasive procedures by translating a surgeon’s hand movements into finer, scaled motions of small instruments inside the patient. Intuitive’s business centers on supplying hospitals and surgical centers with systems, instruments and related technologies that aim to improve precision, visualization and control in the operating room.

In addition to its core surgical platforms, Intuitive markets a portfolio of reusable and disposable instruments, accessories, and proprietary software, and provides training, servicing and clinical support to its customers.